Investors Face August Deadline in ADMA Biologics Securities Lawsuit

The legal action, captioned Mazzarino v. ADMA Biologics, Inc., alleges that the company and its top executives violated the Securities Exchange Act of 1934 by disseminating misleading statements. Plaintiffs contend the company failed to disclose inadequate internal controls and used aggressive sales practices to create a false appearance of growth. These allegations gained traction following a March 2026 report from Culper Research, which claimed the company's reported 20% revenue growth was a fabrication that masked an actual 3% decline.

Market reaction to these disclosures was immediate. Following the Culper report, ADMA Biologics stock dropped more than 16%. The following day, after Cantor Fitzgerald downgraded the stock from Overweight to Neutral, the share price fell an additional 13%. While the company issued a statement characterizing the short-seller report as speculative and inaccurate, the legal challenge continues to move forward. Investors seeking to lead the class action must demonstrate a significant financial interest and meet specific adequacy requirements under the Private Securities Litigation Reform Act of 1995.